

## **Addendum:**

### **Erratum**

Following the appraisal committee on 18<sup>th</sup> May 2010, it was noted that within the ERG report the titles for Figure 14 (p.131), Figure 15 (p.132), Figure 18 (p.135) and Figure 19 (p.136) were incorrect. The correct titles for these figures are as follows:

- Figure 14: Plot of the Kaplan-Meier data and Weibull distribution for PFS for PLDH as monotherapy (estimated by the ERG using individual patient data from the OVA-301 Trial)
- Figure 15: Plot of the Kaplan-Meier data and Weibull distribution for PFS for trabectedin in combination with PLDH (estimated by the ERG using individual patient data from the OVA-301 Trial)
- Figure 18: Plot of the Kaplan-Meier data and Gompertz distribution for PFS for PLDH as monotherapy (estimated by the ERG using individual patient data from the OVA-301 Trial)
- Figure 19: Plot of the Kaplan-Meier data and Gompertz distribution for PFS for trabectedin in combination with PLDH (estimated by the ERG using individual patient data from the OVA-301 Trial)